Bone Biologics Corp Operating Income Loss

• Bone Biologics Corp showed an increase of +23.3% in Operating Income Loss from 2024 to 2025.
• This data is from Bone Biologics Corp's annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), Bone Biologics Corp's Operating Income Loss has declined by 381.4%.
• Historical annual values: Fiscal year 2025: -$3.23 million | Fiscal year 2024: -$4.22 million | Fiscal year 2023: -$9.43 million | Fiscal year 2022: -$3.67 million | Fiscal year 2021: -$1.10 million | Fiscal year 2020: -$825.0 thousand | Fiscal year 2019: -$2.45 million | Fiscal year 2018: -$2.79 million | Fiscal year 2017: -$2.63 million | Fiscal year 2016: -$20.41 million | Fiscal year 2015: -$12.00 million | Fiscal year 2014: -$3.01 million | Fiscal year 2013: -$672.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026